
CASI Pharmaceuticals CASI
Quarterly report 2022-Q3
added 11-14-2022
CASI Pharmaceuticals Depreciation & Amortization 2011-2026 | CASI
Annual Depreciation & Amortization CASI Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 468 K | 562 K | 603 K | 366 K | 118 K | 66.5 K | 68.4 K | 48.2 K | 17.4 K | 20.5 K | 38.1 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 603 K | 17.4 K | 216 K |
Quarterly Depreciation & Amortization CASI Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 567 K | 105 K | 92 K | - | 393 K | 307 K | 179 K | - | 389 K | 276 K | 146 K | - | 561 K | 624 K | 139 K | - | 250 K | 142 K | 65.8 K | - | 69.4 K | 37.9 K | 18.5 K | - | 48 K | 32.5 K | 19 K | - | 50.8 K | 33.2 K | 16.5 K | - | 32.7 K | 19.2 K | 6.53 K | - | 12.9 K | 9.04 K | 4.66 K | - | 15.1 K | 9.38 K | 4.23 K | - | 33.6 K | 23.7 K | 12.1 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 624 K | 4.23 K | 132 K |
Depreciation & Amortization of other stocks in the Biotechnology industry
| Issuer | Depreciation & Amortization | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Acorda Therapeutics
ACOR
|
31.7 M | - | -24.86 % | $ 820 K | ||
|
Adverum Biotechnologies
ADVM
|
3.65 M | - | - | $ 86.2 M | ||
|
AlloVir
ALVR
|
13 K | - | 4.14 % | $ 49.1 M | ||
|
Amgen
AMGN
|
5.17 B | $ 340.0 | -0.75 % | $ 183 B | ||
|
Amneal Pharmaceuticals
AMRX
|
57.3 M | $ 12.32 | -0.24 % | $ 3.86 B | ||
|
Applied Molecular Transport
AMTI
|
3.13 M | - | - | $ 10.1 M | ||
|
I-Mab
IMAB
|
23.9 M | - | - | $ 866 M | ||
|
Arcutis Biotherapeutics
ARQT
|
700 K | $ 23.27 | -1.63 % | $ 2.96 B | ||
|
Autolus Therapeutics plc
AUTL
|
8.3 M | $ 1.36 | -2.16 % | $ 362 M | ||
|
AVROBIO
AVRO
|
617 K | - | 1083.1 % | $ 745 M | ||
|
Ayala Pharmaceuticals
AYLA
|
162 K | - | - | $ 7.46 M | ||
|
BeiGene, Ltd.
BGNE
|
142 M | - | 0.49 % | $ 251 B | ||
|
CymaBay Therapeutics
CBAY
|
681 K | - | - | $ 3.45 B | ||
|
Advaxis
ADXS
|
369 K | - | -9.65 % | $ 45.9 M | ||
|
Aytu BioScience
AYTU
|
5.38 M | $ 2.57 | -3.38 % | $ 16.1 M | ||
|
Avid Bioservices
CDMO
|
11.1 M | - | - | $ 789 M | ||
|
Cidara Therapeutics
CDTX
|
154 K | - | - | $ 1.41 B | ||
|
Cellectar Biosciences
CLRB
|
214 K | $ 2.75 | 1.48 % | $ 7.17 M | ||
|
Aeterna Zentaris
AEZS
|
58 K | - | 5.93 % | $ 314 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
66 K | - | - | $ 231 M | ||
|
AgeX Therapeutics
AGE
|
100 K | - | -10.17 % | $ 12.2 K | ||
|
Concert Pharmaceuticals
CNCE
|
1.48 M | - | - | $ 401 M | ||
|
Aeglea BioTherapeutics
AGLE
|
744 K | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
1.51 M | - | - | $ 26.5 M | ||
|
CTI BioPharma Corp.
CTIC
|
1.95 M | - | - | $ 1.2 B | ||
|
AIkido Pharma
AIKI
|
105 K | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
22 K | - | -45.71 % | $ 1.2 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
5 K | - | -4.36 % | $ 27 M | ||
|
Cyclerion Therapeutics
CYCN
|
65 K | $ 3.48 | -16.14 % | $ 8.76 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.1 M | - | - | $ 2.18 B | ||
|
Akero Therapeutics
AKRO
|
18 K | - | - | $ 3.67 B | ||
|
Dynavax Technologies Corporation
DVAX
|
4.63 M | - | - | $ 2.02 B | ||
|
Coherus BioSciences
CHRS
|
1.3 M | $ 1.67 | - | $ 196 M | ||
|
Akari Therapeutics, Plc
AKTX
|
14 K | $ 3.8 | 7.34 % | $ 256 B | ||
|
Akouos
AKUS
|
2.49 M | - | 0.23 % | $ 488 M | ||
|
Allakos
ALLK
|
6.14 M | - | - | $ 28.6 M |